Personalized follow-up care after nasopharyngeal cancer treatment

Plain-English translation of NCT07590024 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new approach to deciding who needs extra treatment after completing standard radiation and chemotherapy for nasopharyngeal cancer. Instead of giving all patients the same follow-up treatment, doctors will use a personalized prediction tool called RAIRI that looks at your tumor's response during treatment and blood markers to predict your individual risk. Patients at low risk will skip extra medication, while those at higher risk will receive either a or .

Currently, all patients with advanced nasopharyngeal cancer receive extra medication after their main treatment, even though many may not need it. This causes unnecessary side effects, longer treatment, extra costs, and reduced quality of life. The trial aims to use new science about how your tumor responds during treatment to give only those who truly need it the extra medication.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have been diagnosed with non-metastatic nasopharyngeal cancer (stage II–III disease)
you have completed or are about to complete standard radiation and chemotherapy treatment
you have good overall health and organ function, with acceptable blood cell and liver/kidney values
you are willing to undergo follow-up imaging and blood tests and commit to regular clinic visits

You likely don't qualify if…

you have cancer that has spread to distant parts of your body
you have a history of other cancers (except skin or cervical precancers)
you are pregnant, breastfeeding, or unwilling to use contraception
you have serious medical conditions such as recent heart attack, uncontrolled diabetes, active hepatitis B or C, or HIV infection
you cannot commit to regular follow-up appointments and monitoring

What participation looks like

You will receive standard radiation and chemotherapy (with or without initial chemotherapy, as your doctor decides). After treatment, you will have imaging scans and blood tests to measure how well your tumor responded. Using this information, a computer model will classify you as either low-risk or high-risk. If low-risk, you will simply be monitored with regular visits and scans. If high-risk, you will receive additional medication (either a given by IV every 3 weeks or a pill called taken daily) for up to one year, followed by regular monitoring.

Personalized follow-up care after nasopharyngeal cancer treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)